TY - JOUR
T1 - Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation
AU - Couriel, Daniel R.
AU - Hicks, Krystal
AU - Giralt, Sergio
AU - Champlin, Richard E.
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 2000
Y1 - 2000
N2 - Tumor necrosis factor (TNF)-alpha is a central cytotoxic and proinflammatory cytokine. Research on the benefits of TNF-alpha inhibition as a form of therapy has focused almost exclusively on autoimmune, inflammatory disorders. InflixiMAB, a chimeric antibody to human TNF-alpha, was recently approved for the management of Crohn disease and rheumatoid arthritis. The potential applications of inflixiMAB in the management of cancer are just beginning to be explored. This article reviews the biology, mechanism of action, pharmacology, and toxicity of inflixiMAB. Existing clinical experience and inflixiMAB's potential role as an immunosuppressant and antitumor agent in the management of cancer are also discussed.
AB - Tumor necrosis factor (TNF)-alpha is a central cytotoxic and proinflammatory cytokine. Research on the benefits of TNF-alpha inhibition as a form of therapy has focused almost exclusively on autoimmune, inflammatory disorders. InflixiMAB, a chimeric antibody to human TNF-alpha, was recently approved for the management of Crohn disease and rheumatoid arthritis. The potential applications of inflixiMAB in the management of cancer are just beginning to be explored. This article reviews the biology, mechanism of action, pharmacology, and toxicity of inflixiMAB. Existing clinical experience and inflixiMAB's potential role as an immunosuppressant and antitumor agent in the management of cancer are also discussed.
UR - http://www.scopus.com/inward/record.url?scp=0034514152&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034514152&partnerID=8YFLogxK
U2 - 10.1097/00001622-200011000-00011
DO - 10.1097/00001622-200011000-00011
M3 - Review article
C2 - 11085458
AN - SCOPUS:0034514152
SN - 1040-8746
VL - 12
SP - 582
EP - 587
JO - Current opinion in oncology
JF - Current opinion in oncology
IS - 6
ER -